News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Conference News HFSA 2023 STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization L.A. McKeown October 18, 2023
News Conference News HFSA 2023 PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization L.A. McKeown October 12, 2023
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News HFSA 2020 Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study L.A. McKeown October 12, 2020
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Conference News HFSA 2020 More HF Readmissions Among Black People From Deprived Neighborhoods L.A. McKeown October 06, 2020
News Conference News HFSA 2019 Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention L.A. McKeown September 24, 2019
News Conference News HFSA 2019 Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF L.A. McKeown September 23, 2019
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019